T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Canadian Natural Resources
CNQ
|
+$759M |
| 3 |
Becton Dickinson
BDX
|
+$735M |
| 4 |
Ashland
ASH
|
+$669M |
| 5 |
Keysight
KEYS
|
+$573M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$1.73B |
| 2 |
Ecolab
ECL
|
+$1.17B |
| 3 |
Crown Castle
CCI
|
+$906M |
| 4 |
Phillips 66
PSX
|
+$775M |
| 5 |
Gilead Sciences
GILD
|
+$756M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.84% |
| 2 | Consumer Discretionary | 13.93% |
| 3 | Financials | 13.41% |
| 4 | Industrials | 12.4% |
| 5 | Technology | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZU
551
DELISTED
ZULILY INC CLASS A COMMON STOCK
ZU
| $126M | 0.03% |
5,378,237
+1,166,954
| +28% | +$35.8M |
|
552
HP
HPQ
$26.8B
| $126M | 0.03% |
6,900,079
+67,854
| +1% | +$1.14M |
|
553
Highwoods Properties
HIW
$3.46B
| $125M | 0.03% |
2,824,337
-14,310
| -0.5% | -$607K |
|
|
CLVS
554
DELISTED
Clovis Oncology, Inc.
CLVS
| $124M | 0.03% |
2,213,404
+945,153
| +75% | +$49.7M |
|
555
United Therapeutics
UTHR
$21.9B
| $124M | 0.03% |
956,895
+100,389
| +12% | +$12.9M |
|
556
Chord Energy
CHRD
$7.53B
| $124M | 0.03% |
7,470,356
-338,025
| -4% | -$8.38M |
|
557
Quanta Services
PWR
$102B
| $123M | 0.03% |
4,340,361
-2,442,080
| -36% | -$76.7M |
|
558
TriNet
TNET
$3.07B
| $123M | 0.03% |
3,927,518
+660,499
| +20% | +$19.4M |
|
|
CNL
559
DELISTED
CLECO CRP (HOLDING CO)
CNL
| $123M | 0.03% |
2,251,360
-108,400
| -5% | -$5.72M |
|
|
EIGI
560
DELISTED
Endurance International Group Holdings, Inc.
EIGI
| $123M | 0.03% |
6,658,058
+2,175,458
| +49% | +$35.8M |
|
561
TJX Companies
TJX
$169B
| $123M | 0.03% |
3,578,414
+31,938
| +0.9% | +$1.02M |
|
|
HR
562
DELISTED
Healthcare Realty Trust Incorporated
HR
| $123M | 0.03% |
4,488,030
+250,346
| +6% | +$6.52M |
|
|
EPAY
563
DELISTED
Bottomline Technologies Inc
EPAY
| $122M | 0.03% |
4,840,650
+301,830
| +7% | +$7.77M |
|
564
Omnicom Group
OMC
$23.5B
| $121M | 0.03% |
1,566,179
+62,679
| +4% | +$4.57M |
|
565
ESCO Technologies
ESE
$7.78B
| $121M | 0.03% |
3,288,060
+140,500
| +4% | +$5.03M |
|
566
General Mills
GIS
$20.4B
| $121M | 0.03% |
2,260,847
-1,181,751
| -34% | -$61.1M |
|
567
Alnylam Pharmaceuticals
ALNY
$30B
| $120M | 0.03% |
1,242,026
-1,942,036
| -61% | -$180M |
|
568
Kinder Morgan
KMI
$70.7B
| $120M | 0.03% |
2,836,667
+1,758,595
| +163% | +$69.3M |
|
569
Enpro
NPO
$7.23B
| $120M | 0.03% |
1,907,522
-117,400
| -6% | -$7.4M |
|
|
RAVN
570
DELISTED
Raven Industries Inc
RAVN
| $119M | 0.03% |
4,742,600
| – | – |
|
|
JBTM
571
JBT Marel
JBTM
$6.15B
| $117M | 0.02% |
3,564,945
+30,700
| +0.9% | +$940K |
|
572
Wintrust Financial
WTFC
$11B
| $116M | 0.02% |
2,481,500
-15,100
| -0.6% | -$684K |
|
|
WDR
573
DELISTED
Waddell & Reed Financial, Inc.
WDR
| $115M | 0.02% |
2,312,158
+332,685
| +17% | +$15.9M |
|
574
Perrigo
PRGO
$1.76B
| $114M | 0.02% |
683,678
-2,187,166
| -76% | -$342M |
|
|
AIRM
575
DELISTED
Air Methods Corp
AIRM
| $114M | 0.02% |
2,586,551
-351,100
| -12% | -$16.4M |
|
Similar funds
T. Rowe Price Associates's Q4 2014 Portfolio in Review
As of Q4 2014, T. Rowe Price Associates held 2,627 positions worth $471B, up 2.8% from $458B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q4 2014 filing shows 87 new, 929 increased, 999 reduced and 89 closed positions. Its largest new stake was Keysight: 17,553,953 shares worth $593M. The largest sale was RTX Corp, an estimated $1.73B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q4 2014 buy was Keysight: 17,553,953 shares worth $593M.
- T. Rowe Price Associates added most to Allergan plc in Q4 2014, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2014 reduction was RTX Corp, cutting an estimated $1.73B.
- T. Rowe Price Associates fully exited ATHLON ENERGY INC COM in Q4 2014, selling an estimated $499M.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $471B portfolio in Q4 2014.
- T. Rowe Price Associates opened 87 new positions and closed 89 in Q4 2014.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $471B.
Based on T. Rowe Price Associates's 13F filing for Q4 2014, filed 13 Feb 2015.